ReviewTranslational cancer research2020
Research progress of cancer stem cells and IL-6/STAT3 signaling pathway in esophageal adenocarcinoma.
Review in Translational cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- The Diverse Function of IL-6 in Biological Processes and the Advancement of Cancer.Immune network · 2025Review
- The Role of Inflammation in Cancer: Mechanisms of Tumor Initiation, Progression, and Metastasis.Cells · 2025Review
- A NovelClinical Medicine Insights. Oncology · 2024Article
- Correlations between peripheral blood biomarkers and clinical outcomes in advanced non-small cell lung cancer patients who received immunotherapy-based treatments.Translational lung cancer research · 2021Article
- Bioinformatics analysis reveals biomarkers with cancer stem cell characteristics in kidney renal clear cell carcinoma.Translational andrology and urology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal epithelial malignancy can be divided into esophageal squamous cell carcinoma (ESCC) and adenocarcinoma (EAC). EAC is currently the seventh leading cause of death in US. Although ESCC occurs frequently in China and the population of EAC is mostly distributed in the western countries, with the change of lifestyle, diabetes, smoking, gastroesophageal exhalation disease, Barrett's esophagus (BE) and obesity have been confirmed as high-risk factors of EAC. The number of those high-risk groups in China is increasing, and the incidence of EAC in China is likely to increase in the future. At present, there is no clear epidemiological data of EAC in China. Attention should be paid to the pathogenesis, treatment plan and prognosis of EAC. In 2018, updated epidemiological data from the national institutes of health showed that the mortality rate of EAC patients diagnosed between 1975 and 2015 was as high as 91.6%. Currently, it is believed that the causes of poor prognosis, low survival rate, recurrence, metastasis, chemotherapy resistance and radiation resistance of malignant tumors may be closely related to the existence of cancer stem cells (CSCs). This paper reviews the source of BE, the CSC markers of EAC, the correlation among bile acid, IL-6/STAT3 signaling pathway and EAC, as well as the possible source of CSCs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.